Phospholipase A2: New lessons from endothelial cells

Microvascular Research

Volumn 80, Issue 2, 2010, Pages 280-285

  Alberghina, Mario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Angiogenesis; Arachidonic acid; Atherosclerosis; Co cultures; Endothelial cells; Mitogen activated protein kinases (MAPKs); Pericytes; Prostaglandins; Tumor cells

Indexed keywords

ARACHIDONIC ACID; CERAMIDE 1 PHOSPHATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; VASCULOTROPIN;

ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; ENDOTHELIUM CELL; GENE EXPRESSION; GLIOMA; HUMAN; INFLAMMATION; MACROPHAGE; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 77955430661     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.03.013     Document Type: Review

References (57)

1. 2. Biol. Pharm. Bull. 2004, 27:1174-1178.
2. 2 protein expression through activation of PKCα and the MAPK/ERK cascade. J. Lipid Res. 2007, 48:782-793.
3. 2 signaling is required for human melanoma-enhanced brain endothelial cell proliferation and motility. Microvasc. Res. 2009, 78:338-357.
4. 2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J. Biol. Chem. 2006, 281:187-198.
5. 2. Br. J. Pharmacol. 2001, 134:197-205.
6. 2 receptors EP3 and EP4 in the nuclear envelope. J. Biol. Chem. 1999, 274:15719-15724.
7. 2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50:S237-S242.
8. 2: mediators of inflammation, proliferation and apoptosis. Prog. Lipid Res. 2001, 40:167-197.
9. 2. FEBS Lett. 2002, 522:113-118.
10. 2 in the invasion of brain microvascular endothelial cells by Escherichia coli and Listeria monocytogenes. J. Infect. Dis. 2001, 184:732-737.
11. Edelman D.A., Jiang Y., Tyburski J., Wilson R.F., Steffes C. Pericytes and their role in microvasculature homeostasis. J. Surg. Res. 2006, 135:305-311.
12. 2 isoforms in advanced stage ovarian carcinoma. Gynecol. Oncol. 2006, 103:831-840.
13. Grabb P.A., Gilbert M.R. Neoplastic and pharmacological influence on the permeability of an in vitro blood brain barrier. J. Neurosurg. 1995, 82:1053-1058.
14. Gracia-Sancho J., Laviña B., Rodríguez-Vilarrupla A., García-Calderó H., Bosch J., García-Pagán J.C. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J. Hepatol. 2007, 47:220-227.
15. Grewal S., Morrison E.E., Ponnambalam S., Walker J.H. Nuclear localisation of cytosolic phospholipase A2-alpha in the EA.hy.926 human endothelial cell line is proliferation dependent and modulated by phosphorylation. J. Cell Sci. 2002, 115:4533-4543.
16. 2 mediates endothelial cell S phase progression. J. Biol. Chem. 2006, 281:35709-35716.
17. Hutterer M., Gunsilius E., Stockhammer G. Molecular therapies for malignant glioma. Wien Med. Wochenschr. 2006, 156:351-363.
18. 2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Pathol. 2002, 160:667-671.
19. 2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells. Mol. Pharmacol. 1996, 50:1139-1147.
20. 2 signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat. 2009, 90:31-36.
21. 2 on human endothelial cell function. FASEB J. 2006, 20:2547-2549.
22. 2. Biochem. Biophys. Res. Commun. 2005, 327:287-293.
23. 2: review of its role as a marker and a potential participant in coronary endothelial dysfunction. Mol. Diagn. Ther. 2007, 11:219-226.
24. 2 in vitro and in activated human monocytes. Cell Signal. 2007, 19:359-366.
25. 2 mediates arachidonoyl phospholipid hydrolysis in immortalized rat brain endothelial cells stimulated by oxidized LDL. Biochim. Biophys. Acta 2002, 1585:19-29.
26. 2 and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells. Biochim. Biophys. Acta 2005, 1735:135-150.
27. 2+-independent phospholipase C. Biochim. Biophys. Acta 1987, 917:296-307.
28. 2 mediates CREB phosphorylation in double-stranded RNA-stimulated endothelial cells. J. Lipid Res. 2003, 44:1686-1691.
29. Martin-Venegas R., Roig-Perez S., Ferrer R., Moreno J.J. Arachidonic acid cascade and epithelial barrier function during Caco-2 cell differentiation. J. Lipid Res. 2006, 47:1416-1423.
30. 2 is regulated by a novel protein kinase C in human coronary artery endothelial cells. Am. J. Physiol. Cell Physiol. 2005, 288:C475-C482.
31. 2 inhibitors. Biochem. Pharmacol. 2002, 63:321-332.
32. 2. J. Biol. Chem. 1993, 268:839-844.
33. 2. J. Biol. Chem. 2005, 280:24987-24998.
34. Nakagawa S., Deli M.A., Kawagichi H., Shimizudani T., Shimono T., Kittel A., Tanaka K., Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009, 54:253-263.
35. 2α and arachidonic acid in cancer. Biochim. Biophys. Acta 2006, 1761:1335-1343.
36. Norel X. Prostanoid receptors in the human vascular wall. Scientific World J. 2007, 7:1359-1374.
37. 2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim. Biophys. Acta 2006, 1761:1309-1316.
38. 2 in the translocation of hypoxia-inducible factor-1α to the nucleus under hypoxic conditions. Eur. J. Pharmacol. 2006, 549:58-62.
39. 2 activity. Mol. Vis. 2004, 10:341-350.
40. 2) and MAP kinase in human endothelial cells. Biochem. Biophys. Res. Commun. 1996, 218:500-504.
41. 2. J. Biol. Chem. 2004, 279:11320-11326.
42. 2 activity in rat C6 glioma cells. Biochem. Mol. Biol. Int. 1995, 35:363-370.
43. 2 prevents inflammatory mediator production in pulmonary microvascular endothelium. Resp. Physiol. Neurobiol. 2009, 165:167-174.
44. 2 inhibitors. Prostaglandins Leukot. Essent. Fatty Acids 2007, 76:205-212.
45. 2 in bladder microvascular endothelial cells. Am. J. Physiol. Renal Physiol. 2005, 288:F714-F721.
46. Rizza C., Leitinger N., Yue J., Fischer D.J., Wang D.A., Shih P.T., Lee H., Tigyi G., Berliner J.A. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab. Invest. 1999, 79:1227-1235.
47. 2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J. Biol. Chem. 1995, 270:2360-2366.
48. Schiera G., Sal S., Gallo A., Raffa M.P., Pitarresi G.L., Savettieri G., Di Liegro I. Permeability properties of a three-cell type in vitro model of blood-brain barrier. J. Cell. Mol. Med. 2005, 9:373-379.
49. 2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell 2001, 33:233-240.
50. 2 and cyclooxygenases in human melanocytes and malignant melanoma cell lines. Biochim. Biophys. Acta 2008, 1781:635-642.
51. 2 is in the nucleus of subconfluent endothelial cells but confined to the cytoplasm of confluent endothelial cells and redistributes to the nuclear envelope and cell junctions upon histamine stimulation. Lab. Invest. 1996, 74:684-695.
52. 2, lipoxygenase, and cyclooxygenase. Mol. Cell. Biochem. 2008, 315:97-112.
53. 2 in human monocytic cells. J. Biol. Chem. 2004, 279:22505-22513.
54. 2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol. Carcinog. 2007, 46:912-923.
55. 2. J. Nutr. 2005, 135:1847-1853.
56. 2 enhances cell migration in non-apoptotic ovarian cancer cells. J. Biol. Chem. 2006, 281:29357-29368.
57. 2, PAF, and LPA1 receptors. Can. J. Physiol. Pharmacol. 2006, 84:377-391.